Compare ABG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABG | ACAD |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.9B |
| IPO Year | 2001 | 2000 |
| Metric | ABG | ACAD |
|---|---|---|
| Price | $189.02 | $20.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 22 |
| Target Price | ★ $251.33 | $30.45 |
| AVG Volume (30 Days) | 191.0K | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.88 | ★ 69.12 |
| EPS | ★ 25.13 | 2.30 |
| Revenue | ★ $17,999,000,000.00 | $726,437,000.00 |
| Revenue This Year | $6.03 | $18.52 |
| Revenue Next Year | $2.48 | $11.34 |
| P/E Ratio | ★ $7.54 | $8.82 |
| Revenue Growth | 4.71 | ★ 40.45 |
| 52 Week Low | $186.27 | $14.08 |
| 52 Week High | $274.50 | $28.35 |
| Indicator | ABG | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 22.40 | 36.97 |
| Support Level | N/A | $20.45 |
| Resistance Level | $255.30 | $22.75 |
| Average True Range (ATR) | 6.50 | 0.90 |
| MACD | -1.14 | -0.15 |
| Stochastic Oscillator | 15.04 | 18.76 |
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 152 new-vehicle stores and 37 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 14 states (mostly Texas, the West, the Mid-Atlantic, and the Southeast). Asbury store brands include McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated $17.2 billion of revenue in 2024 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.